Oramed Pharmaceuticals Inc (ORMP)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $169.59M
Last updated: Nov 17, 2026 at 4:15 PM ET
Oramed Pharmaceuticals Inc (ORMP) Statistics
Oramed Pharmaceuticals (ORMP) has a market cap of $169.59M. Revenue fell 100.00% over the last 12 months from the 12 months before. Its dividend yield is 6.46%.
Total Valuation
| Market Cap | $169.59M |
|---|---|
| Latest price (Nov 17, 2026) | $3.87 |
Key Dates
The next earnings report is expected on Mar 24, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Jan 16, 2026.
| Next Earnings Date | Mar 24, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Last Ex-Dividend Date | Jan 16, 2026 |
| Last Payment Date | Jan 26, 2026 |
| Fiscal Year End | December |
Valuation Ratios
| P/E Ratio | 4.2x |
|---|---|
| Forward P/E | 0.8x |
| P/B Ratio | 0.5x |
Price Statistics
The stock is up 77.38% over 52 weeks and trades 10.42% below its 50-day average.
| Beta (1Y) | 1.18 |
|---|---|
| 52-Week Change | +77.38% |
| 1-Month Change | -4.68% |
| 3-Month Change | -19.21% |
| 6-Month Change | -10.62% |
| 5-Year Change | -82.44% |
| 10-Year Change | -38.10% |
| Total Return (1Y) | +88.83% |
| Total Return (3Y CAGR) | +26.32% |
| Total Return (5Y CAGR) | -31.64% |
| Return vs SPY (1Y) | +54.42% |
| Max Drawdown (1Y) | -30.52% |
| Max Drawdown (3Y) | -44.13% |
| Sharpe Ratio (1Y) | 0.96 |
| Correlation with SPY (1Y) | 0.31 |
| 50-Day Average | $4.32 |
| 200-Day Average | $4.06 |
| 52-Week Range | $2.22 to $5.47 |
| RSI (14 Days) | 41.8 |
| Average Volume (20 Days) | 124.21K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 6.07x current liabilities.
| Current Ratio | 6.07x |
|---|---|
| Quick Ratio | 6.07x |
| Interest Coverage | 1.99x |
Returns and Efficiency
Return on equity is 42.73% over the last 12 months, against a 5-year average of -4.34%.
| Return on Equity (ROE) | 42.73% |
|---|---|
| Return on Assets (ROA) | 36.14% |
| ROE (5Y Average) | -4.34% |
| ROA (5Y Average) | -4.55% |
| ROIC (5Y Average) | -4.23% |
Taxes
Income tax took 23.38% of pretax income over the last 12 months.
| Income Tax (TTM) | $44.22M |
|---|---|
| Effective Tax Rate | 23.38% |
Scores
ORMP has a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 2 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$60.00K |
| Operating Income | -$16.20M |
| Pretax Income | $189.10M |
| Net Income | $144.88M |
| Reported EPS (TTM) | $0.91 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 84.58% of the $400.92M in total assets.
| Cash and Equivalents | $28.93M |
|---|---|
| Working Capital | $47.93M |
| Shareholder Equity | $339.09M |
| Book Value Per Share | $7.88 |
| Total Assets | $400.92M |
| Total Liabilities | $61.83M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $213.00K of capital spending, operating cash flow left -$3.37M of free cash flow.
| Operating Cash Flow | -$3.15M |
|---|---|
| Capital Expenditures | $213.00K |
| Free Cash Flow | -$3.37M |
| FCF Per Share | -$0.08 |
| Depreciation and Amortization | $121.00K |
| Dividends Paid | $31.73M |
Trailing 12 months through Sep 30, 2026.
Growth
Revenue fell 9.55% a year over 3 years.
| Revenue Growth (3Y CAGR) | -9.55% |
|---|---|
| Revenue Growth (5Y CAGR) | -5.90% |
| Book Value Per Share Growth (2Y CAGR) | +10.32% |
| Tangible Book Per Share Growth (2Y CAGR) | +10.32% |
Dividends and Yields
ORMP pays out 7.42% of earnings as dividends.
| Dividend Per Share (Annual) | $0.25 |
|---|---|
| Dividend Yield | 6.46% |
| Payout Ratio | 7.42% |
| Earnings Yield | 23.81% |
| FCF Yield | -2.02% |
| Shareholder Yield | 19.06% |
Stock Splits
The last split was a 1-for-12 reverse split on Jan 23, 2013.
| Last Split Date | Jan 23, 2013 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:12 |
Analyst Forecast
Consensus estimates put EPS growth at 198.00% a year over the next fiscal year.
| EPS Growth Forecast (1Y CAGR) | +198.00% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About ORMP
What is ORMP's market cap?
Oramed Pharmaceuticals has a market cap of $169.59M.
What is ORMP's P/E ratio?
Oramed Pharmaceuticals has a trailing P/E ratio of 4.2x and a forward P/E of 0.8x.
How many shares of ORMP are outstanding?
Oramed Pharmaceuticals has 43.02M shares outstanding. The count is up 0.56% from a year earlier.
Does ORMP pay a dividend?
Yes. Oramed Pharmaceuticals pays $0.25 a share a year, a dividend yield of 6.46%.
ORMP pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors